Enhanced anticancer efficiency of doxorubicin against human glioma by natural borneol through triggering ROS-mediated signal

Biomedicine & Pharmacotherapy

卷:118

Ya-jun Hou¹  Xiao-yan Fu¹  Bai-song Zhao²  Ying Li³  Xue-qi Fu⁴  Mao-xun Yang⁵  Wen-qiang Cao⁶  Han-ming Jiang⁷ 

[1] Phamaceutical Institute, Hengqin New Area, Zhuhai, Guangdong, 519000, China;

[2] Shandong Academy of Medical Sciences, Taian, Shandong, 271000, China;

[3] Zhuhai Hopegenes Medical &

[4] Department of Biochemistry, Basic Medicine College, Shandong First Medical University &

[5] Department of Pediatrics, Shandong Provincial ENT Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China;

[6] School of Life Sciences, Jilin University, Changchun, Jilin, 130012, China;

关键词: Doxorubicin;    Natural borneol;    ROS;    DNA damage;    Chemosensitizer;   

DOI  :  

来源: DOAJ

【 摘 要 】

Doxorubicin (DOX) as a first-line chemotherapeutic drug has been widely used for therapy of human cancers. However, side effects and chemo-resistance severely blocked its clinic application. Herein, natural borneol (NB) as a novel monoterpenoid chemosensitizer was found to have the potential to increase the blood brain barrier (BBB) permeability and intracellular uptake of DOX in vitro, and synergistically enhanced DOX-induced cytotoxicity in human glioma cells. NB treatment significantly potentiated DOX-induced G2/M cell cycle arrest by triggering reactive oxygen species (ROS)-mediated DNA damage. NB also enhanced DOX-induced dysfunction of MAPKs and PI3 K/AKT pathways. Furthermore, U251 human glioma xenograft growth in vivo was also effectively inhibited by combined treatment of DOX with NB through induction of G2/M-phase arrest and antiangiogenesis. Taken together, our finding validated that NB could act as novel chemosensitizer to enhance DOX-induced anticancer efficacy, and strategy of using NB and DOX could be a high efficient way in therapy of human cancers.

【 授权许可】

Unknown